Schering Clarinex Reditabs approved
Executive Summary
Schering-Plough's Clarinex Reditabs 5 mg clears FDA June 26 for treatment of allergy symptoms and chronic idiopathic urticaria. Product launch is "pending FDA approval of a quality control test revision, the supplement for which has already been submitted, and the build-up of sufficient inventories," the company said. Reditabs have been "approvable" since December (1"The Pink Sheet" Dec. 24, 2001, p. 34)...
You may also be interested in...
Schering Clarinex Approval Comes In Time For Big Spring Push
Schering-Plough has received approval for the Claritin successor Clarinex in time to permit a big market build-up for the spring allergy season
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.